FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: Implications for clinical outcome in acute myeloid leukaemia

European Journal of Haematology

Volumn 67, Issue 4, 2001, Pages 221-229

  Nørgaard, Jan M ^a   Olesen, Lene H ^a   Olesen, Gitte ^a   Meyer, Karin ^a   Kristensen, Jørgen S ^a   Bendix, Knud ^a   Pedersen, Bent ^a   Kjeldsen, Eigil ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

FAB subtype; Immunophenotype; Leukaemia cell drug resistance; Prognosis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACLARUBICIN; ANTHRACYCLINE DERIVATIVE; ANTILEUKEMIC AGENT; CD14 ANTIGEN; CYTARABINE; DAUNORUBICIN; NUCLEOSIDE ANALOG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL PROTOCOL; FEMALE; HUMAN; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

ACLARUBICIN; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMSACRINE; ANTIGENS, CD14; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; COHORT STUDIES; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; MULTIVARIATE ANALYSIS; THIOGUANINE; TREATMENT OUTCOME; TUMOR STEM CELLS;

EID: 0035706238     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00553.x     Document Type: Article

References (35)

1. All-trans retinoic acid (ATRA) therapeutical effect in acute promyelocytic leukemia
2. In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells
3. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
4. Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin
5. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498
6. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia
7. Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside in vitro
8. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia
9. Leukaemia cell drug resistance and prognostic factors in AML
10. Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia
11. Monoclonal antibodies in myeloid diseases: Prognostic use in acute myeloid leukaemia
12. Prognostic value of immunophenotyping in acute myeloid leukemia
13. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of study AML-BFM-87
14. Proposals for the classification of acute leukaemias
15. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0)
16. Proposed revised criteria for the classification of acute myeloid leukaemia
17. Acute myeloid leukemia
18. Cellular drug resistance profiles in childhood acute myeloid leukemia: Differences between FAB types and comparison with acute lymphoblastic leukemia
19. MDR1 gene expression and drug resistance of AML cells
20. Relation of blast cell survival and proliferation to chemotherapy resistance in AML
21. Arabinosyl cytosine: Useful agent in the treatment of acute leukemia in adults
22. Improved flow cytometric identification of myelopoiesis by the simultaneous labelling with CD13, CD14 and CD66 monoclonal antibodies
23. Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: Identification of a group of patients with similar T-cell receptor beta and delta rearrangements and course of disease suggestive of poor prognosis
24. First-line diagnosis based on immunological phenotyping in suspected acute leukemia: A prospective study
25. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: A Danish national phase III trial
26. Specific minor chromosome deletions consistently occuring in myelodysplastic syndromes
27. The importance of diagnostic cytogenetics on outcome in AML. Analysis of 1,612 patients entered into the MRC AML 10 trial
28. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling
29. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein
30. Differences in CD14 and alpha-naphthyl acetate esterase positivity and relation to prognosis in AML
31. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
32. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies
33. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia
34. Multidrug resistance is more than MDR1 activity
35. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia